Company Akili, Inc.

Equities

AKLI

US00974B1070

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq 23:00:00 09/05/2024 BST 5-day change 1st Jan Change
0.4272 USD -3.87% Intraday chart for Akili, Inc. +6.37% -12.30%

Business Summary

Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company’s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Number of employees: 68

Sales per Business

USD in Million2022Weight2023Weight Delta
Digital Medicine Platform
100.0 %
0 100.0 % 2 100.0 % +419.50%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 2 100.0 % +419.50%

Managers

Managers TitleAgeSince
Chief Executive Officer 50 31/07/22
Founder 42 30/11/20
Chief Tech/Sci/R&D Officer - 30/11/22
Corporate Officer/Principal 46 -
Human Resources Officer - 28/02/18
General Counsel 65 31/07/22

Members of the board

Members of the board TitleAgeSince
Director/Board Member 60 31/07/22
Director/Board Member 65 24/10/22
Director/Board Member 54 02-15
Director/Board Member 47 31/07/22
Founder 42 30/11/20
Founder 55 30/11/20
Chief Executive Officer 50 31/07/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 78,509,823 60,079,279 ( 76.52 %) 0 76.52 %

Shareholders

NameEquities%Valuation
The Social+Capital Partnership LLC
15.11 %
11,873,000 15.11 % 3 M $
Temasek Holdings Pte Ltd.
14.64 %
11,509,122 14.64 % 3 M $
LB Hercules Holdings LLC
7.350 %
5,776,784 7.350 % 2 M $
4,699,219 5.979 % 1 M $
Baillie Gifford & Co.
5.936 %
4,665,795 5.936 % 1 M $
Suvretta Capital Management LLC
4.888 %
3,841,718 4.888 % 1 M $
Jazz Venture Partners, LLC
4.780 %
3,756,590 4.780 % 1 M $
2,310,753 2.940 % 670 118 $
1,089,314 1.386 % 315 901 $
Comprehensive Financial Management LLC (California)
1.353 %
1,063,422 1.353 % 308 392 $

Company contact information

Akili, Inc.

71 Commercial Street

02109, Boston

+

http://www.akiliinteractive.com
address Akili, Inc.(AKLI)